InflaRx Explores Expanded AAV Strategy After EMA Revokes Tavneos Approval
Event summary
- InflaRx is evaluating a broader development strategy for ANCA-associated vasculitis (AAV) in Europe following the EMA's recommendation to revoke Tavneos' marketing authorization on June 26, 2026.
- The company plans to engage with the EMA regarding both vilobelimab and izicopan to determine the most efficient regulatory path for AAV treatment.
- Phase 2 planning for izicopan in AAV continues uninterrupted across multiple geographies.
- Vilobelimab is considered a Phase 3-ready asset, having completed two Phase 2 studies in the U.S. and Europe.
The big picture
The EMA's decision to revoke Tavneos' approval underscores the critical need for well-characterized, mechanistically targeted therapies in AAV. InflaRx's dual approach with vilobelimab and izicopan positions it to capitalize on this gap, though regulatory hurdles and clinical trial outcomes will dictate its success. The broader biotech landscape is watching how complement system inhibitors like these will perform against existing treatments.
What we're watching
- Regulatory Pathway
- How InflaRx's engagement with the EMA will shape the regulatory strategy for vilobelimab and izicopan in AAV.
- Clinical Progress
- The pace at which Phase 2 planning for izicopan in AAV advances across different geographies.
- Competitive Positioning
- Whether InflaRx can leverage its C5a/C5aR inhibition mechanism to address the unmet medical need in AAV following Tavneos' revocation.
Related topics